Corden Pharma Experts taking care. APIs DRUG PRODUCTS FACILITIES PLATFORMS ABOUT US CONTACT US News and Press Home About Us News and Press CordenPharma Chenôve Receives Successful FDA Inspection Aug 31, 2016 CordenPharma is pleased to announce that their CordenPharma Chenôve (France) manufacturing facility recently completed an FDA Inspection and received a successful response with no 483s reported. The last FDA Inspection took place in 2014. Interview >> Dr. Michael Quirmbach >> A Decade of CordenPharma Jul 25, 2016 Pharmaceutical Technology Interviews Dr. Michael Quirmbach, Vice President, Global Marketing & Sales, CordenPharma International > A Decade of CordenPharma > From Inception to Full‑Service Provider Interview >> EuroPeptides Interviews Dr. Mimoun Ayoub on Peptide Vaccines Jul 20, 2016 EuroPEPTIDES, part of Tides Europe taking place November 14 - 17, 2016 in Berlin, Interviews Dr. Mimoun Ayoub, Director, Peptides, Lipids, Carbohydrates & Injectables Platforms on Peptide Vaccines. CordenPharma Enters Oligonucleotide API Manufacturing Market Jul 01, 2016 CordenPharma is pleased to announce its expansion into the oligonucleotide Active Pharmaceutical Ingredient (API) development and manufacturing market in CordenPharma Colorado (USA) to further strengthen its CDMO offering. CordenPharma Caponago Announces Successful Approval of New Sterile Injectable Facility Jun 28, 2016 CordenPharma is pleased to announce the completion and approval of its aseptic filling line in CordenPharma Caponago (IT) by the Italian AIFA for clinical and commercial supply. Article >> Colorado Department of Public Health & Environment Profiles CordenPharma Colorado Jun 24, 2016 The Colorado Department of Public Health and Environment (CDPHE) Office of Health Equity profiles the environmental leadership and community outreach programs of CordenPharma Colorado. Poster Abstract >> International Carbohydrate Symposium > by Dr. Stewart Campbell Jun 21, 2016 View an abstract of the poster to be given at the International Carbohydrate Symposium, July 17-20, 2016 at the New Orleans Marriott, LA >> by Dr. Stewart Campbell, Head of Business Development & Product Management, Carbohydrates >> Title: Protection against experimental melioidosis with a synthetic beta-manno-heptopyranose hexasaccharide glycoconjugate Event >> CordenPharma & Weylchem Run in Frankfurt J.P. Morgan Corporate Challenge Jun 15, 2016 CordenPharma & Weylchem participated in the 2016 J.P. Morgan Corporate Challenge, which took place June 15th in Frankfurt, Germany. CordenPharma Latina Receives USFDA Warning Letter May 27, 2016 CordenPharma International would like to notify customers about a warning letter received from the USFDA on May 24, 2016 in its CordenPharma Latina facility in Sermoneta, Italy. This action follows an earlier inspection of the site by the agency in May 2015. This matter is being considered throughout the organization with the utmost sense of urgency. Interview >> Ernesto Petroselli, President of CordenPharma > CEO Europe Magazine, June 2016 May 20, 2016 A Healthy Outlook The pharmaceutical industry is booming, and global giant CordenPharma is well positioned to share in the spoils with its offering of a one-stop supply shop. CordenPharma Arranges a Syndicated Loan of EUR 60 Million May 02, 2016 ICIG’s CordenPharma Group today announced the closing of a syndicated loan of EUR 60 Million. CordenPharma successfully closed its first syndicated loan on advantageous terms. Article >> Chemistry Today Oligos & Peptides, March / April 2016 > by Dr. Mimoun Ayoub Apr 22, 2016 Drug Conjugation > How Technology Drives the Supply Chain by Dr. Mimoun Ayoub Director, Global Peptides, Lipids, Carbohydrates & Injectables Platforms, CPI Article >> Chemistry Today Oligos & Peptides, March / April 2016 >> by Dr. Stewart Campbell Apr 22, 2016 Targeted Delivery of Nucleic Acids via Carbohydrate-Protein Interactions by Dr. Stewart Campbell Head of Business Development & Product Management, Carbohydrates, CordenPharma Switzerland Article >> Drug Development & Delivery, April 2016 > Luca Porcu Contribution Apr 13, 2016 Read CordenPharma's article contribution titled CordenPharma: Full-Service Capabilities Geared to Meeting Aggressive Timelines from Luca Porcu, Director, Global Small Molecules Platform, in the Drug Development & Delivery April 2016 special feature on 'Outsourcing Formulation Development & Manufacturing: Using a Single Provider Reduces Costs & Risk'. Caisson Establishes Global Manufacturing Partnership with CordenPharma Apr 13, 2016 AUSTIN, Texas & OKLAHOMA CITY >> Caisson Biotech, LLC (Caisson), a leader in half-life extension and drug delivery, today announced it has established a global manufacturing partnership with CordenPharma International (CordenPharma), a full-service Contract Development & Manufacturing Organization (CDMO) manufacturing APIs and Drug Products through a network of cGMP facilities across Europe and the US. CordenPharma Announcements at DCAT Week '16 > Dr. Roberto Margarita Apr 07, 2016 During the DCAT Member Forum on Monday, March 14, 2016 of DCAT Week '16 at the Waldorf Astoria in New York City, Dr. Roberto Margarita, Director, Global Antibiotics, Highly Potent & Oncology Platforms, CPI, presented 4 CordenPharma announcements to the DCAT Community. ICIG Completes Acquisition of Sandoz Site in Frankfurt-Höchst > Corden BioChem GmbH Apr 01, 2016 International Chemical Investors Group (ICIG) today announced the completion of its acquisition of Sandoz Industrial Products GmbH, a Frankfurt-Höchst based manufacturer of enzyme-based fermentation products and intermediates for the pharmaceutical industry, from Novartis Group. Sandoz Industrial Products GmbH will be re-named Corden BioChem GmbH and will be associated with the CordenPharma Group, the pharma platform of ICIG. Video >> CordenPharma Plankstadt Expanded Highly Potent Development Facility Mar 30, 2016 Click here to watch a video fo the newly expanded CordenPharma Plankstadt Highly Potent Development facility. CordenPharma Announces Expanded Aseptic & Oral Development Capabilities Mar 14, 2016 As part of a long term strategy to meet increasing customer demands, CordenPharma has completed two additional key investments to strengthen its development and manufacturing capabilities for Drug Product service offerings across its Highly Potent, Oncology and Injectables Platforms. DCAT 2016 Interview Abstract >> Chemistry Today Jan-Feb 2016 >> Dr. Michael Quirmbach Mar 03, 2016 Where do you see your company's role in the pharmaceutical supply chain? With well-structured product & service offerings organized under the umbrella of six distinctive technology platforms – Peptides/Lipids/Carbohydrates, Injectables, Antibiotics, Highly Potent, Oncology and Small Molecules - CordenPharma is well-positioned as a key CDMO supplier and partner to the pharmaceutical industry. ICIG Acquires Sandoz Site in Frankfurt-Höchst Feb 24, 2016 International Chemical Investors Group (ICIG) and Novartis Group have entered into an agreement under which ICIG will acquire all of the shares in Sandoz Industrial Products GmbH, a Frankfurt-Höchst based manufacturer of enzyme-based fermentation products and intermediates for the pharmaceutical industry, especially for the use in antibiotics. Closing of the transaction is anticipated to occur on 1 April 2016. News >> CordenPharma Colorado FDA Audit > Success Feb 16, 2016 CordenPharma Colorado announces successful results from their recent 5 Day Intensive FDA Audit: no 483-observations and a No Action Indicated (NAI) status. Interview >> IBC Interviews Tides 2016 Speaker Dr. Mimoun Ayoub Feb 02, 2016 IBC interviews upcoming Tides 2016 Speaker Dr. Mimoun Ayoub, Director, Global Peptides, Lipids, Carbohydrates & Injectables Platforms, on the role peptide vaccines play in the development of novel cancer therapies. Orpegen Facility Moves to Frankfurt to become CordenPharma Frankfurt Jan 25, 2016 Following the acquisition of ORPEGEN Peptide Chemicals GmbH on January 1, 2015, CordenPharma International announces that on July 1,2015, the non-GMP facility and personnel moved to a location in Frankfurt-Fechenheim now called CordenPharma Frankfurt. Video >> Optimising the Product-Performance Model > Panel at Pharma Integrates 2015 Dec 16, 2015 View the video of the Pharma Integrates 2015 panel discussion Optimising the Product-Performance Model with panelist Luca Porcu, Director, Global Highly Potent & Small Molecules Platforms. DCAT Annouces New Advisory Council Member Dr. Roberto Margarita Oct 30, 2015 Robbinsville, NJ, USA > October 26, 2015 – The Drug, Chemical & Associated Technology Association (DCAT) is pleased to announce that Dr. Roberto Margarita, Director, Global Antibiotics & Oncology Platforms at CordenPharma International has been elected by the membership to serve on DCAT’s Advisory Council for a three-year term beginning November 1, 2015. Article >> Chimica Oggi, Sept 2015 > Critical Aspects of Robust Potent Compound Containment > by Amy Doane & Robin Livingston, CordenPharma Colorado Oct 07, 2015 Amy Doane & Robin Livingston of CordenPharma Colorado discuss innovative solutions to ensure containment of Highly Potent Active Pharmaceutical Ingredients (HPAPIs). Article >> Specialty Chemicals, Sept 2015 > Containing Highly Potent Ingredients > by Dr. Roberto Margarita & Luca Porcu Oct 06, 2015 Dr. Roberto Margarita, Director of the Global Antibiotics & Oncology Platforms, and Luca Porcu, Director of the Global Highly Potent & Small Molecules Platforms, look at the many elements needed for a successful containment progamme. CordenPharma Latina Approved for Clinical Supply of Sterile Oncology Lyophilised Products Jul 13, 2015 CordenPharma is pleased to announce that the Sterile Oncology Suite in its CordenPharma Latina (IT) manufacturing facility has received approval for Clinical Supply of Sterile Oncology Lyophilised Products. Article >> Pharmaceutical Technology, June 2015 > Dr. Roberto Margarita Thought Leader Profile Jul 06, 2015 Dr. Roberto Margarita, Director, Global Antibiotics & Oncology Platforms, CPI - Pharmaceutical Technology Thought Leader Profile - Resistance to Antibiotics is Driving A New Product Wave With Innovative Challenges. Article >> CordenPharma Colorado Named in SafeBridge Potent Compound Certification Update Jul 03, 2015 In a recent article in Manufacturing Chemist Pharma, CordenPharma Colorado was mentioned in an update by SafeBridge Consultants as a manufacturing organisation which continues to maintain effective performance in the recognition, evaluation and control of highly potent compounds. ICIG Obtained EC Approval for Acquisition of Certain Chlorovinyls Assets Being Divested by INEOS Jun 09, 2015 International Chemical Investors Group (ICIG) recently announced an agreement with INEOS and Solvay to acquire certain chlorovinyls assets being divested by INOVYN / INEOS. This agreement, which has been reviewed in the context of the merger control process of both this transaction and the INOVYN JV, has now received approval of the European Commission. The closing of the acquisition of the remedy business by ICIG is anticipated to be August 1, 2015. Cover Story >> Chemica Oggi Peptide Supplement, April 2015 > by Dr. Mimoun Ayoub May 11, 2015 Cover Story >> Peptide Vaccines: A Promising Therapeutic Approach. Addressing the CMC Challenges > Chemica Oggi Oligo & Peptide Supplement, April 2015 > by Dr. Mimoun Ayoub, Global Director, Peptides / Lipids / Carbohydrates & Injectables Platforms, CPI. Article >> Chimica Oggi Peptide Supplement, April 2015 > Dr. Mimoun Ayoub Interview May 09, 2015 Article >> The Expansion of the Therapeutic Applications of Peptides: Drivers & Challenges > Chimica Oggi Oligo & Peptide Supplement, April 2015 > Interview of Dr. Mimoun Ayoub, Global Director, Peptides / Lipids / Carbohydrates & Injectables Platforms, CPI. Article >> EuroAsia Industry Magazine > Ernesto Petroselli Interview May 08, 2015 Article >> Prospects Through Pharmaceutical Partnership > EuroAsia Industry Magazine, Issue 4/2015 > Interview by Ernesto Petroselli, Presdident, CordenPharma International. Article >> Drug Development & Delivery, April 2015 > Dr. Roberto Margarita Contribution May 08, 2015 Article >> Outsourcing Formulation & Manufacturing Development > Drug Development & Delivery, April 2015, Volume 15 > Contribution by Dr. Roberto Margarita, Global Director Antibiotics & Oncology Platforms, CPI CordenPharma Wins 2015 CMO Industry Choice Award Mar 18, 2015 CordenPharma is the winner of the 2015 Life Science Leader CMO Leadership Industry Choice Award for Big Pharma on March 18th at their awards ceremony in New York City. Nanobiotix Appoints CordenPharma as Manufacturing Partner Mar 18, 2015 Nanobiotix, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces it has appointed CordenPharma as its manufacturing partner. CordenPharma Switzerland US Catalogue Order Processing Change Mar 03, 2015 Effective March 5, 2015, CordenPharma Switzerland announces a transfer and change to the US Catalogue Product order process for small pack Phospholipids (1g and 10g) and Pseudoprolines (10g and 25g). Peptisyntha Announces Successful FDA Inspection Mar 02, 2015 Peptisyntha, a CordenPharma facility near Brussels, Belgium, announces a successful completion of their recent FDA inspection. CordenPharma to Receive 9 Life Science Leader CMO Leadership Awards in 2015 Feb 19, 2015 On Wednesday March 18, 2015 CordenPharma will be recognized with 9 CMO Leadership Awards presented by Life Science Leader magazine. The Life Science Leader CMO Leadership Awards are determined through industry research conducted by Nice Insight. CordenPharma Acquires the Assets of ORPEGEN Peptide Chemicals GmbH Jan 16, 2015 On January 1, 2015 CordenPharma International acquired the assets of Orpegen Peptide Chemicals GmbH, located in Heidelberg, Germany, retaining both their experienced personnel and peptide capabilities. The newly acquired subsidiary, to be named CordenPharma Heidelberg, will provide innovative, cutting-edge process research and non-GMP development services. CordenPharma Plankstadt Announces Successful FDA Inspection Oct 27, 2014 CordenPharma Plankstadt announces today successful results from their recent 5 day intensive FDA Inspection: no 483-observations were found and no recommendations were given. CordenPharma Colorado Named Among Top Places to Work Apr 28, 2014 The Denver Post recently named CordenPharma Colorado as one of the Top Places to Work in Colorado. CordenPharma Switzerland Transfers Amino Acid Building Blocks Portfolio to Chemie Uetikon GmbH Feb 21, 2014 Effective February 1, 2014, CordenPharma Switzerland transfers their Amino Acid Building Blocks portfolio to Chemie Uetikon GmbH, based in Lahr, Germany CordenPharma Colorado Receives Potent Compound Safety Certification Approval from SafeBridge® Jan 27, 2014 CordenPharma Colorado announces receipt of approval for the "Potent Compound Safety Certification" by SafeBridge® Consultants, Inc. for the safe handling of potent APIs and compounds of unknown toxicity and potency. CordenPharma Acquires Ancora's Carbohydrate Synthesis Platform Nov 01, 2013 On October 31, 2013 CordenPharma acquired Ancora Pharmaceuticals, located in Woburn, MA, USA. Ancora’s unique carbohydrate synthesis technology platform and chemistry research facilities perfectly complement CordenPharma’s capabilities in the manufacture and supply of high-quality complex synthetic molecules. ICIG to acquire Allessa from Cassella Sep 25, 2013 International Chemical Investors Group (ICIG) and Casella GmbH have reached an agreement in principle under which ICIG would acquire all of the shares of Allessa GmbH. Both parties have agreed not to disclose the purchase price. CordenPharma Caponago Granted SHE Certification Sep 03, 2013 CordenPharma Caponago was recently granted SHE Certification with an OH SAS 18001:2007 Certificate for the maintenance of their Safety Management System involving manufacturing activities and the packaging and control of injectable liquid, freeze-dried and powder products. CordenPharma to Acquire Peptisyntha from Solvay Aug 28, 2013 International Chemical Investors Group (ICIG) and the Solvay Group have entered into an agreement under which ICIG will acquire Peptisyntha SA, the Brussels, Belgium, based custom manufacturer of peptides for pharmaceutical use. Upon closing of the deal, expected later this fall, Peptisyntha will become a member of ICIG’s CordenPharma platform as its third site offering peptides manufacturing. CordenPharma Colorado Boosts Boulder as Innovation Hub Jun 13, 2013 In an article on June 7th of The Boulder County Business Report, the city of Boulder, Colorado was cited for national recognition as an innovation hub in various informal polls. ICIG Announces New CordenPharma Management Team Jun 03, 2013 ICIG announced today changes in the management of CordenPharma, its pharmaceutical contract manufacturing business. What Does it Take to Produce 25 kg of Peptides? May 06, 2013 Visit our upcoming poster Development of a Scalable Process for CNP-22, presented by Valerie Paulsen, Principal Analytical Chemist, CordenPharma Colorado at Tides 2013, May 12 - 15 in Boston. Interview of CordenPharma Colorado's Brad DeHoff by Phenomenex Apr 05, 2013 In a recent issue of their e-newslettter PrepLC eNews, the R&D staff at Phenomenex interviews Dr. Brad DeHoff, Director of R&D for CordenPharma Colorado, about current and future trends of the CMO industry. ICIG kicks off €50+ million investment at PPC in Thann, France Mar 22, 2013 International Chemical Investors Group (ICIG) kicks off €50+ million investment at PPC, a company of WeylChem Group, the fine chemicals platform of ICIG, to develop membrane-based technology. PPC is located in Thann, France. CordenPharma Colorado Named Approved Peptide Supplier for Linaclotide Mar 08, 2013 In an article published on March 4th in Chemical & Engineering News, CordenPharma Colorado was named an approved peptide supplier to Ironwood Pharmaceuticals for their product Linaclotide: CordenPharma Colorado Regional Science Fair 2013 Mar 05, 2013 On Thursday, February 28th CordenPharma Colorado sponsored and sent 3 scientists to serve as jurors for the CordenPharma Colorado Regional Science Fair, which took place at on the University of Colorado campus in Boulder. CordenPharma Expands with ICIG Acquisition of Farchemia Feb 13, 2013 CordenPharma announces an expansion of manufacturing capabilities due to the recent acquisition by International Chemical Investors Group (ICIG) of Farchemia from the Tessenderlo Group, completed on December 5th, 2012. CordenPharma Chenôve Receives Certificates from Japan PDMA and French ANSM Dec 13, 2012 CordenPharma Chenôve receives updated certificate of compliance to cGMP standards from the PDMA in Japan and the ANSM in France. CordenPharma Caponago Receives WCA Achievement Award Nov 30, 2012 CordenPharma Caponago Receives Workplace Conditions Assessment (WCA) Achievement Award Enabled by Intertek. Orifarm Generics Names CordenPharma Best Supplier Oct 24, 2012 Today Orifarm Generics announced that CordenPharma was elected as the Best Supplier in the Orifarm Generics' Supplier Evaluation 2012. CordenPharma Presents European Outsourcing Award at CPhI 2012 Oct 10, 2012 CordenPharma presents the award for the Most Effective Process Development/Scale-Up Programme at the European Outsourcing Awards on October 10th in Madrid during CPhI 2012. And the winner is.... Tessenderlo Group Intention to Sell Pharmaceutical Ingredients Activities Oct 09, 2012 Tessenderlo Group (NYSE Euronext: TESB) announced today that it has the intention to sell its pharmaceutical ingredients activities, Farchemia and Calaire Chimie, to International Chemical Investors Group (ICIG), a private industrial holding company. The sale concerns two production sites in France and Italy. CordenPharma Paclitaxel Approved in Europe Oct 05, 2012 Today CordenPharma announced the approval of our proprietary generic drug product dossier for Paclitaxel in the reference state (Germany). With this approval CordenPharma is now open to out-licensing the generic Paclitaxel dossier with rights to register, promote and market the drug to esteemed customers in all EU territories. CordenPharma to Sponsor Boulder Peptide Symposium 2012 Aug 09, 2012 CordenPharma will be Gold Sponsors of the Boulder Peptide Symposium, taking place September 26-28, 2012 at the St. Julien Hotel and Spa in Boulder, CO. Read the full story for Discounted Registration Information. CordenPharma Colorado Named Among Top 50 Businesses in Boulder Jul 31, 2012 In the Boulder Daily Camera's annual list of Top 50 Largest Businesses, CordenPharma Colorado ties with Google Inc. at Number 42 ~ click here for the Daily Camera's full article. Frost & Sullivan Acclaims CordenPharma for Achieving Excellence in Product Differentiation Feb 16, 2012 Based on its recent analysis of the pharmaceutical contract manufacturing market, Frost & Sullivan recognises CordenPharma with the 2011 Western Europe Frost & Sullivan Award for Product Differentiation Excellence. International Chemical Investors Group Announces Acquisition of CordenPharma Colorado from Roche Oct 06, 2011 We are pleased to announce that on September 1, 2011 International Chemical Investors Group (ICIG) acquired a former division of Roche to join their pharmaceutical platform CordenPharma International as CordenPharma Colorado. International Chemical Investors Group Announces Agreement to Acquire Pharmaceutical Intermediates Business from Genzyme Corporation Feb 03, 2011 Luxembourg – International Chemical Investors Group (ICIG) announced that it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation. Contact our team of experts to place an inquiry. CONTACT US About Us Leadership Our History Compliance News and Press Events ICIG Careers Browse brochures & presentations to learn more about CordenPharma. RESOURCE CENTER Corden Pharma ©2012 CordenPharma International Media Contact Impressum Terms and Conditions Privacy Policy Website by Boston Interactive Facebook LinkedIn Corden Pharma International GmbH, Otto-Hahn-Strasse, 68723 Plankstadt, Germany. APIs API Development API Contract Manufacturing Generic API Manufacturing Highly Potent APIs Sterile APIs Peptides Building Blocks Conjugate Products Carbohydrates Derivatized Phospholipids Support Services Drug Products Drug Product Development Drug Product Contract Manufacturing Sterile Formulation Highly Potent Formulation Oncology Cephalosporin Manufacturing Penicillin Manufacturing Parenterals Large Pre-Filled Syringes Sterile Oncology Oral Oncology Two-layer tablets Clinical Supply Services Packaging Pharma-Logistics Support Services Facilities Bergamo, IT Boulder, US Brussels, BE Caponago, IT Chenôve, FR Latina, IT Liestal, CH Plankstadt, DE CordenBioChem Platforms Antibiotics Highly Potent & Oncology Small Molecules Peptides, Lipids & Carbohydrates Injectables Fermentation & Enzymes About Us Leadership Our History Compliance News and Press Events ICIG Careers Contact Us Find Your Expert Schedule an Appt